Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Insiders At Y-mAbs Therapeutics Sold US$4.5m In Stock, Alluding To Potential Weakness
While Shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
Y-mAbs Therapeutics Price Target Maintained With a $23.00/Share by Wedbush
Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study
Y-mAbs Therapeutics Announced New Clinical And Preclinical Data From Studies Evaluating Naxitamab And GD2-SADA, Respectively, In Neuroblastoma
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Y-mAbs to Participate in Upcoming Investor Conferences in September
The 21% Return This Week Takes Y-mAbs Therapeutics' (NASDAQ:YMAB) Shareholders One-year Gains to 178%
Cantor Fitzgerald Initiates Coverage on Y-mAbs Therapeutics With Overweight Rating, $20 Price Target
Cantor Fitzgerald Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $20
Cantor Fitzgerald analyst Li Watsek initiates coverage on $Y-mAbs Therapeutics(YMAB.US)$ with a buy rating, and sets the target price at $20.According to TipRanks data, the analyst has a success
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
CCORF analyst John Newman maintains $Y-mAbs Therapeutics(YMAB.US)$ with a buy rating, and maintains the target price at $26.According to TipRanks data, the analyst has a success rate of 37.6% and a
Y-mAbs Therapeutics Shares Are Trading. The Stock May Be Rebounding After Falling Earlier in the Week on Weak Earnings and Guidance.
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
Truist Financial analyst Nicole Germino maintains $Y-mAbs Therapeutics(YMAB.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate
A Quick Look at Today's Ratings for Y-mAbs Therapeutics(YMAB.US), With a Forecast Between $21 to $26
On Aug 13, major Wall Street analysts update their ratings for $Y-mAbs Therapeutics(YMAB.US)$, with price targets ranging from $21 to $26.BMO Capital analyst Etzer Darout maintains with a buy rating,
HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target